NCT04298008View on ClinicalTrials.gov

AZD6738 Plus Durvalumab in Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Bile Duct CancerChemotherapy Effect
Interventions
DRUG

AZD6738

AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks

DRUG

Durvalumab

Durvalumab 1500 mg iv on D1 Every 4 weeks

Trial Locations (1)

110-744

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04298008 - AZD6738 Plus Durvalumab in Biliary Tract Cancer | Biotech Hunter | Biotech Hunter